Advent Technologies Reports Q4 2022 Results
Advent Technologies Holdings reported Q4 2022 revenue of $2.0 million, down 22% year-over-year, and a full-year total of $7.8 million, up 18%. The net loss for Q4 stood at $47.6 million or $(0.92) per share, heavily impacted by a $38.9 million impairment charge. The company has cash reserves of $32.9 million as of Dec 31, 2022. Advent is pursuing funding of €782.1 million for the Green HiPo project, aiming to create 600 direct jobs. The newly opened R&D facility in Boston will enhance product scalability. Joint developments with Hyundai and projects in marine applications are underway, showcasing Advent's growth strategy.
- Full-year revenue increased by 18% year-over-year to $7.8 million.
- Opening of a new R&D and manufacturing facility in Boston, aimed at scaling production.
- Secured €782.1 million funding for the Green HiPo project, anticipated to create 600 direct and 4,600 indirect jobs.
- Joint Development Agreement with Hyundai for advanced fuel cell technology.
- Increased global demand for fuel cells and advanced membranes expected to boost future revenue.
- Q4 2022 revenue decreased by 22% compared to Q4 2021.
- Significant net loss of $47.6 million in Q4, including a large impairment charge.
- Cash reserves fell by $9.5 million from the previous quarter.
-
Q4 2022 revenue of
and income from grants of$2.0 million .$0.4 million -
Full year 2022 revenue of
and income from grants of$7.8 million .$1.5 million -
Net loss in Q4 of
or$47.6 million per share, including an impairment charge of$(0.92) . Adjusted net loss in Q4 of$38.9 million or$13.2 million per share.$(0.26) -
Company holds unrestricted cash reserves of
as of$32.9 million December 31, 2022 . -
After official ratification from the
European Commission of theEuropean Union for funding of€782.1 million under the Important Projects of Common European Interest (“IPCEI”) Hydrogen – Technology for Advent’s Green HiPo project, Advent has been working with the Greek State to establish the mechanism and timing schedule for the funding facility. -
Commissioning of new Hood Park R&D and manufacturing facility in
Boston, Massachusetts . This facility will enable Advent to scale-up and deliver on the increasing global demand for its electrochemical products.
Q4 2022 Financial Highlights
(All comparisons are to Q4 2021, unless otherwise stated)
-
Revenue of
and income from grants of$2.0 million . The total of$0.4 million is down$2.4 million 22% year-over-year, due to a decline in orders for the Company’s stationary fuel cell systems primarily driven by a change in tower ownership by certainPhilippines telecom operators. -
Full year 2022 revenue of
and income from grants of$7.8 million . The total of$1.5 million is an increase of$9.3 million 18% year-over-year, primarily due to a full year of results from the Company’s fuel cell systems businesses, compared to a partial year post-acquisition in 2021. -
Operating expenses of
, a year-over-year decrease of$11.7 million , primarily due to a reduction in incentive and stock-based compensation expenses.$4.6 million -
Net loss in Q4 of
or$47.6 million per share. Adjusted net loss of$(0.92) or$13.2 million per share. Adjusted net loss excludes a$(0.26) gain from the change in the fair value of outstanding warrants, a$2.1 million gain from an acquisition purchase price adjustment, and a$2.4 million goodwill and intangible asset impairment charge.$38.9 million -
Asset impairment charge primarily relates to goodwill from the Company’s stationary fuel cell systems business in
Denmark ,Germany , andthe Philippines , which was acquired inAugust 2021 . -
Unrestricted cash reserves were
as of$32.9 million December 31, 2022 , a decrease of from$9.5 million September 30, 2022 . In the fourth quarter of 2022, the Company received in tenant improvement allowances for the Hood Park R&D and manufacturing facility in$0.4 million Charlestown, MA , which is net of additional spending for the build-out of the facility.
“Advent continued to make progress in the last quarter, despite global recession and inflationary pressures. Subsequent to ratification by the EU for Advent’s IPCEI Green HiPo project, we have been working with the Greek State on the mechanism and timing schedule for the funding facility. It is our goal to finalize these discussions as soon as possible and proceed with the roll-out of the program,” said Dr.
Business Updates
New Hood Park R&D and Manufacturing Facility: In
Joint Development Agreement with Hyundai Motor Company (“Hyundai”): On
Vantage Towers Greece (“Vantage Towers”): On
Collaboration with Alfa Laval: On
Marine Fuel Cell Solution for Superyachts: On
Honey Badger Fuel Cell for
Conference Call
The Company will host a conference call on
To access the call please dial (888) 660-6182 from
A replay of the call can also be accessed via phone through
About
Cautionary Note Regarding Forward-Looking Statements
This press release includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “plan,” “could,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” and other words of similar meaning. Each forward-looking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the Company’s ability to maintain the listing of the Company’s common stock on Nasdaq; future financial performance; public securities’ potential liquidity and trading; impact from the outcome of any known and unknown litigation; ability to forecast and maintain an adequate rate of revenue growth and appropriately plan its expenses; expectations regarding future expenditures; future mix of revenue and effect on gross margins; attraction and retention of qualified directors, officers, employees, and key personnel; ability to compete effectively in a competitive industry; ability to protect and enhance our corporate reputation and brand; expectations concerning our relationships and actions with our technology partners and other third parties; impact from future regulatory, judicial and legislative changes to the industry; ability to locate and acquire complementary technologies or services and integrate those into the Company’s business; future arrangements with, or investments in, other entities or associations; and intense competition and competitive pressure from other companies worldwide in the industries in which the Company will operate; and the risks identified under the heading “Risk Factors” in our Annual Report on Form 10-K filed with the
Presentation of Non-GAAP Financial Measures
In addition to the results provided in accordance with
|
|||||
CONSOLIDATED BALANCE SHEETS |
|||||
(Amounts in USD thousands, except share and per share amounts) |
|||||
|
As of |
||||
ASSETS |
(Unaudited) |
|
|
||
Current assets: |
|||||
Cash and cash equivalents |
$ |
32,869 |
|
$ |
79,764 |
Accounts receivable |
979 |
|
|
3,139 |
|
Contract assets |
52 |
|
|
1,617 |
|
Inventories |
|
12,620 |
|
|
6,958 |
Prepaid expenses and Other current assets |
2,980 |
|
|
5,873 |
|
Total current assets |
49,500 |
|
97,351 |
||
Non-current assets: |
|
|
|
|
|
|
|
5,742 |
|
|
30,030 |
Intangibles, net |
|
6,062 |
|
|
23,344 |
Property and equipment, net |
17,938 |
|
|
8,585 |
|
Right-of-use assets |
|
4,055 |
|
|
- |
Other non-current assets |
|
5,971 |
|
|
2,475 |
Deferred tax assets |
- |
|
|
1,246 |
|
Available for sale financial asset |
|
320 |
|
|
- |
Total non-current assets |
40,088 |
|
65,680 |
||
Total assets |
$ |
89,588 |
|
$ |
163,031 |
LIABILITIES AND STOCKHOLDERS’ EQUITY |
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
Trade and other payables |
$ |
4,680 |
|
$ |
4,837 |
Deferred income from grants, current |
|
801 |
|
|
205 |
Contract liabilities |
1,019 |
|
|
1,118 |
|
Other current liabilities |
|
4,703 |
|
|
12,515 |
Operating lease liabilities |
|
2,280 |
|
|
- |
Income tax payable |
183 |
|
|
196 |
|
Total current liabilities |
13,666 |
|
18,871 |
||
Non-current liabilities: |
|
|
|
|
|
Warrant liability |
|
998 |
|
|
10,373 |
Deferred tax liabilities |
- |
|
|
2,500 |
|
Long-term operating lease liabilities |
|
9,802 |
|
|
- |
Defined benefit obligation |
|
72 |
|
|
90 |
Deferred income from grants, non-current |
|
50 |
|
|
- |
Other long-term liabilities |
852 |
|
|
996 |
|
Total non-current liabilities |
11,774 |
|
13,959 |
||
Total liabilities |
25,440 |
|
32,830 |
||
Commitments and contingent liabilities |
|
|
|
|
|
Stockholders’ equity |
|
|
|
|
|
Common stock ( |
|
5 |
|
|
5 |
Preferred stock ( |
- |
|
|
- |
|
Additional paid-in capital |
|
174,509 |
|
|
164,894 |
Accumulated other comprehensive loss |
(2,604) |
|
|
(1,273) |
|
Accumulated deficit |
|
(107,762) |
|
|
(33,425) |
Total stockholders’ equity |
64,148 |
|
130,201 |
||
Total liabilities and stockholders’ equity |
$ |
89,588 |
|
$ |
163,031 |
|
|||||||||||
CONSOLIDATED STATEMENTS OF OPERATIONS |
|||||||||||
(Amounts in USD thousands, except share and per share amounts) |
|||||||||||
Three months ended |
Years Ended |
||||||||||
(Unaudited) |
|
(Unaudited) |
|||||||||
2022 |
2021 |
2022 |
2021 |
||||||||
Revenue, net |
$ |
1,957 |
|
$ |
2,903 |
|
$ |
7,837 |
|
$ |
7,069 |
Cost of revenues |
(2,455) |
(2,744) |
(8,581) |
(5,406) |
|||||||
Gross profit / (loss) |
|
(498) |
|
|
159 |
|
|
(744) |
|
|
1,663 |
Income from grants |
449 |
197 |
1,460 |
829 |
|||||||
Research and development expenses |
|
(2,458) |
|
|
(1,980) |
|
|
(9,796) |
|
|
(3,541) |
Administrative and selling expenses |
(9,258) |
(14,318) |
(35,915) |
(41,877) |
|||||||
Amortization of intangibles |
|
(651) |
|
|
(717) |
|
|
(2,764) |
|
|
(1,185) |
Credit loss – customer contracts |
|
(1,116) |
|
|
- |
|
|
(1,116) |
|
|
- |
Gain from purchase price adjustment |
|
2,370 |
|
|
- |
|
|
2,370 |
|
|
- |
Impairment loss - intangible assets and goodwill |
|
(38,922) |
|
|
- |
|
|
(38,922) |
|
|
- |
Operating loss |
|
(50,084) |
|
(16,659) |
|
(85,427) |
|
(44,111) |
|||
Fair value change of warrant liability |
|
2,127 |
|
|
6,909 |
|
|
9,375 |
|
|
22,743 |
Finance income / (expenses), net |
61 |
(24) |
52 |
(51) |
|||||||
Foreign exchange gains / (losses), net |
|
(40) |
|
|
(42) |
|
|
(91) |
|
|
(43) |
Other income / (expenses), net |
4 |
(62) |
(216) |
16 |
|||||||
Loss before income tax |
|
(47,932) |
|
|
(9,878) |
|
|
(76,307) |
|
|
(21,446) |
Income taxes |
307 |
872 |
1,970 |
923 |
|||||||
Net loss |
$ |
(47,625) |
|
$ |
(9,006) |
|
$ |
(74,337) |
|
$ |
(20,523) |
Net loss per share |
|||||||||||
Basic loss per share |
|
(0.92) |
|
|
(0.18) |
|
|
(1.44) |
|
|
(0.45) |
Basic weighted average number of shares |
51,717,720 |
51,253,591 |
51,528,703 |
45,814,868 |
|||||||
Diluted loss per share |
|
(0.92) |
|
|
(0.18) |
|
|
(1.44) |
|
|
(0.45) |
Diluted weighted average number of shares |
51,717,720 |
51,253,591 |
51,528,703 |
45,814,868 |
|||||||
|
|||||
CONSOLIDATED STATEMENTS OF CASH FLOWS |
|||||
(Amounts in USD thousands) |
|||||
Years Ended |
|||||
|
(Unaudited) |
||||
2022 |
2021 |
||||
|
$ |
(32,125) |
|
$ |
(35,837) |
|
|
||||
Cash Flows from Investing Activities: |
|
|
|
|
|
Proceeds from sale of property and equipment |
|
0 |
|
|
7 |
Purchases of property and equipment |
|
(11,527) |
|
(3,920) |
|
Purchases of intangible assets |
|
(117) |
|
|
(18) |
Advances for the acquisition of property and equipment |
|
(2,557) |
|
(2,200) |
|
Acquisition of a subsidiary, net of cash acquired |
|
- |
|
|
(19,425) |
Acquisition of available for sale financial assets |
|
(316) |
|
- |
|
|
$ |
(14,517) |
|
$ |
(25,556) |
|
|||||
Cash Flows from Financing Activities: |
|
|
|
|
|
Business Combination and PIPE financing, net of issuance costs paid |
- |
|
141,121 |
||
Proceeds of issuance of common stock and paid-in capital from warrants exercise |
|
- |
|
|
262 |
State loan proceeds |
- |
|
118 |
||
State refundable deposit repayment |
|
(40) |
|
|
- |
|
$ |
(40) |
|
$ |
141,501 |
|
|||||
Net (decrease) / increase in cash, cash equivalents, restricted cash and restricted cash equivalents |
$ |
(46,682) |
|
$ |
80,108 |
Effect of exchange rate changes on cash, cash equivalents, restricted cash and restricted cash equivalents |
537 |
|
(860) |
||
Cash, cash equivalents, restricted cash and restricted cash equivalents at the beginning of year |
|
79,764 |
|
|
516 |
Cash, cash equivalents, restricted cash and restricted cash equivalents at the end of year |
$ |
33,619 |
$ |
79,764 |
Supplemental Non-GAAP Measures and Reconciliations
In addition to providing measures prepared in accordance with GAAP, we present certain supplemental non-GAAP measures. These measures are EBITDA, Adjusted EBITDA and Adjusted Net Income / (Loss), which we use to evaluate our operating performance, for business planning purposes and to measure our performance relative to that of our peers. These non-GAAP measures do not have any standardized meaning prescribed by GAAP and therefore may differ from similar measures presented by other companies and may not be comparable to other similarly titled measures. We believe these measures are useful in evaluating the operating performance of the Company’s ongoing business. These measures should be considered in addition to, and not as a substitute for net income, operating expense and income, cash flows and other measures of financial performance and liquidity reported in accordance with GAAP. The calculation of these non-GAAP measures has been made on a consistent basis for all periods presented.
EBITDA and Adjusted EBITDA
These supplemental non-GAAP measures are provided to assist readers in determining our operating performance. We believe this measure is useful in assessing performance and highlighting trends on an overall basis. We also believe EBITDA and Adjusted EBITDA are frequently used by securities analysts and investors when comparing our results with those of other companies. EBITDA differs from the most comparable GAAP measure, net income / (loss), primarily because it does not include interest, income taxes, depreciation of property, plant and equipment, and amortization of intangible assets. Adjusted EBITDA adjusts EBITDA for one-time transaction costs, asset impairment charges, changes in warrant liability, and executive severance.
The following tables show a reconciliation of net income / (loss) to EBITDA and Adjusted EBITDA for the three months and years ended
|
Three months ended |
Years Ended |
||||||||||||||
EBITDA and Adjusted EBITDA |
(Unaudited) |
|
(Unaudited) |
|||||||||||||
(in Millions of |
2022 |
2021 |
$ change |
2022 |
2021 |
$ change |
||||||||||
Net loss |
$ |
(47.63) |
|
$ |
(9.00) |
(38.63) |
$ |
(74.34) |
|
$ |
(20.52) |
(53.82) |
||||
Depreciation of property and equipment |
$ |
0.36 |
$ |
0.38 |
(0.02) |
$ |
1.49 |
$ |
0.56 |
0.93 |
||||||
Amortization of intangibles |
$ |
0.65 |
|
$ |
0.71 |
(0.06) |
$ |
2.76 |
|
$ |
1.18 |
1.58 |
||||
Finance income / (expenses), net |
$ |
(0.06) |
$ |
0.02 |
(0.08) |
$ |
(0.05) |
$ |
0.05 |
(0.10) |
||||||
Other income / (expenses), net |
$ |
0.00 |
|
$ |
0.06 |
(0.06) |
$ |
0.22 |
|
$ |
(0.02) |
0.24 |
||||
Foreign exchange differences, net |
$ |
0.04 |
$ |
0.04 |
- |
$ |
0.09 |
$ |
0.04 |
0.05 |
||||||
Income taxes |
$ |
(0.31) |
|
$ |
(0.87) |
0.56 |
$ |
(1.97) |
|
$ |
(0.92) |
(1.05) |
||||
EBITDA |
$ |
(46.95) |
|
$ |
(8.66) |
(38.29) |
$ |
(71.80) |
|
$ |
(19.63) |
(52.17) |
||||
Net change in warrant liability |
$ |
(2.13) |
|
$ |
(6.91) |
4.78 |
$ |
(9.38) |
|
$ |
(22.74) |
13.36 |
||||
Gain from purchase price adjustment |
$ |
(2.37) |
|
$ |
- |
(2.37) |
$ |
(2.37) |
|
$ |
- |
(2.37) |
||||
Impairment loss – intangible assets and goodwill |
$ |
38.92 |
|
$ |
- |
38.92 |
$ |
38.92 |
|
$ |
- |
38.92 |
||||
One-Time Transaction Related Expenses (1) |
$ |
- |
$ |
- |
- |
$ |
- |
$ |
5.87 |
(5.87) |
||||||
One-Time Transaction Related Expenses (2) |
$ |
- |
|
$ |
- |
- |
$ |
- |
|
$ |
0.89 |
(0.89) |
||||
Executive severance (3) |
$ |
- |
$ |
- |
- |
$ |
- |
$ |
2.44 |
(2.44) |
||||||
Adjusted EBITDA |
$ |
(12.53) |
|
$ |
(15.57) |
3.04 |
$ |
(44.63) |
|
$ |
(33.17) |
(11.46) |
(1) Bonus awarded after consummation of the Business Combination effective
(2) Transaction costs related to the acquisition of SerEnergy/
(3) Former Financial Officer resignation.
Adjusted Net Income / (Loss)
This supplemental non-GAAP measure is provided to assist readers in determining our financial performance. We believe this measure is useful in assessing performance and highlighting trends on an overall basis. Adjusted Net Loss differs from the most comparable GAAP measure, net income / (loss), primarily because it does not include one-time transaction costs, asset impairment charges, changes in warrant liability, and executive severance. The following table shows a reconciliation of net income / (loss) for the three months and years ended
|
Three months ended |
Years Ended |
|||||||||||||
Adjusted Net Loss |
(Unaudited) |
|
(Unaudited) |
||||||||||||
(in Millions of |
2022 |
2021 |
$ change |
2022 |
2021 |
$ change |
|||||||||
Net loss |
$ |
(47.63) |
|
$ |
(9.00) |
(38.63) |
$ |
(74.34) |
|
$ |
(20.52) |
(53.82) |
|||
Net change in warrant liability |
$ |
(2.13) |
$ |
(6.91) |
4.78 |
$ |
(9.38) |
$ |
(22.74) |
13.36 |
|||||
Gain from purchase price adjustment |
$ |
(2.37) |
|
$ |
- |
(2.37) |
$ |
(2.37) |
|
$ |
- |
(2.37) |
|||
Impairment loss – intangible assets and goodwill |
$ |
38.92 |
$ |
- |
38.92 |
$ |
38.92 |
$ |
- |
38.92 |
|||||
One-Time Transaction Related Expenses (1) |
$ |
- |
|
$ |
- |
- |
$ |
- |
|
$ |
5.87 |
(5.87) |
|||
One-Time Transaction Related Expenses (2) |
$ |
- |
$ |
- |
- |
$ |
- |
$ |
0.89 |
(0.89) |
|||||
Executive severance (3) |
$ |
- |
|
$ |
- |
- |
$ |
- |
|
$ |
2.44 |
(2.44) |
|||
Adjusted Net Loss |
$ |
(13.21) |
|
$ |
(15.91) |
2.70 |
$ |
(47.17) |
|
$ |
(34.06) |
(13.11) |
(1) Bonus awarded after consummation of the Business Combination effective
(2) Transaction costs related to the acquisition of SerEnergy/
(3) Former Financial Officer resignation.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230331005154/en/
nhussain@advent.energy
press@advent.energy
Source:
FAQ
What were Advent Technologies' Q4 2022 financial highlights?
How much funding did Advent secure for the Green HiPo project?
What is the significance of the new R&D facility opened by Advent?
What was the adjusted net loss for Advent in Q4 2022?